Abstract
Background In 2010, the FDA approved the use of extended-release injectable naltrexone (Vivitrol©) for the treatment of opioid dependence. Preliminary evidence from prior studies indicates that monthly injections of Vivitrol are effective in treating opioid dependence after initial detoxification. This longitudinal exploratory study measures demographics, medication adherence, sobriety (urinalysis), utilization of care, and mental and emotional states in patients who were treated for opioid dependence with injectable naltrexone at an addictions stabilization center.
Highlights
In 2010, the FDA approved the use of extended-release injectable naltrexone (Vivitrol©) for the treatment of opioid dependence
Materials and methods Participants involved in the Vivitrol pilot program (VPP) completed surveys upon intake and before and after each monthly injection
The findings from this study indicate that previous knowledge of extended-release naltrexone and prior medication-assisted treatments (MAT) experience may influence the initiation and commitment to use of this MAT
Summary
In 2010, the FDA approved the use of extended-release injectable naltrexone (Vivitrol©) for the treatment of opioid dependence. Preliminary evidence from prior studies indicates that monthly injections of Vivitrol are effective in treating opioid dependence after initial detoxification. This longitudinal exploratory study measures demographics, medication adherence, sobriety (urinalysis), utilization of care, and mental and emotional states in patients who were treated for opioid dependence with injectable naltrexone at an addictions stabilization center
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have